A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Conditions
- Sarcoma
- Liposarcoma
- Leiomyosarcoma
- Undifferentiated Pleomorphic Sarcoma
Interventions
- DRUG: Eribulin
- DRUG: Pembrolizumab
Sponsor
Dana-Farber Cancer Institute
Collaborators